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a b s t r a c t
Antioxidants probably play an important role in the etiology of type 2 diabetes (DM2). This
study evaluated the effects of supplementation with lipoic acid (LA) and a-tocopherol on the
lipid profile and insulin sensitivity of DM2 patients.
A randomized, double-blind, placebo-controlled trial involving 102 DM2 patients divided
into four groups to receive daily supplementation for 4 months with: 600 mg LA (n = 26);
800 mg a-tocopherol (n = 25); 800 mg a-tocopherol + 600 mg LA (n = 25); placebo (n = 26).
Plasma a-tocopherol, lipid profile, glucose, insulin, and the HOMA index were determined
before and after supplementation. Differences within and between groups were compared
by ANOVA using Bonferroni correction. Student’s t-test was used to compare means of two
independent variables.
The vitamin E/total cholesterol ratio improved significantly in patients supplemented
with vitamin E + LA and vitamin E alone ( p  0.001). There were improvements of the lipid
fractions in the groups receiving LA and vitamin E alone or in combination, and on the
HOMA index in the LA group, but not significant.
The results suggest that LA and vitamin E supplementation alone or in combination did
not affect the lipid profile or insulin sensitivity of DM2 patients.
# 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license.
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including a reduction of high-density lipoprotein cholesterol
(HDL-c) and an increase of plasma triglycerides (TG) and low-
density lipoprotein cholesterol (LDL-c) concentrations, with
the last fraction being the most susceptible to oxidation in
patients with DM2 [3].
The use of antioxidants such as lipoic acid (LA) and vitamin
E has been proposed as a strategy to correct disturbances in
carbohydrate and lipid metabolism [4]. LA is naturally
synthesized by animals and humans. This acid plays a role
in lipid metabolism in the liver, kidneys and blood and
participates in various enzymatic complexes that are funda-
mental for the metabolism of carbohydrates. In addition, LA
increases glucose transport in muscle cells, an activity that
might be related to its antioxidant properties [5]. In an
experimental study on the treatment of DM2, Blumenthal
[6] demonstrated the hypoglycemic action of LA on liver
function. Two randomized, double-blind, placebo-controlled
multicenter studies investigated the effects of this acid on
peripheral neuropathy in patients with DM2. The ALADIN
(Alpha-Lipoic Acid in Diabetic Neuropathy) [7] and DEKAN
(Deutsche Kardiale Autonome Neuropathie) [8] studies
reported the improvement of symptoms of peripheral neu-
ropathy (pain, burning sensation, paresthesia, and numbness)
and of autonomic cardiac dysfunction. Supplementation with
LA seems to be important for the control of diabetic
neuropathy [5], but the results regarding the reduction of
oxidative stress, insulin deficiency and improvement of lipid
profile in humans are inconclusive since animal models were
used in the studies [9,10].
Vitamin E is a potential dietary antioxidant and an
important component of cell membranes. In addition to its
antioxidant properties, vitamin E reduces cytotoxicity, mini-
mizes the effect of oxidized lipoproteins, suppresses the
proliferation of smooth muscle cells, reduces platelet adhe-
sion and aggregation, and improves endothelial function [11].
The effect of vitamin E on oxidative stress, in the antioxidant
defense system and insulin resistance in patients with DM2
was investigated in a clinical trial using supplementationwith
800 IU vitamin E/day. The study showed a reduction of
atherogenic lipid fractions in the diabetic group [12]. Hsu
et al. [13] reported a positive effect of thismicronutrient on the
oxidation of LDL-c in patients with DM2 who received
supplementation with 1200 IU a-tocopherol/day for 3 months.
On the other hand, no positive effect was observed in obese
patients with DM2 who received 600 IU vitamin E/day for 3
months, with this supplementation even deteriorating the
action of insulin [14]. Similarly, a recent study involving obese
men supplemented with 50 mg a-tocopherol/day found no
protective effect on cardiovascular outcomes [15]. However,
evidence indicates the presence of low a-tocopherol concen-
trations in patients with DM2 and these levels are even lower
when there are complications of the disease [16].
In view of the important relationship between increased
oxidative stress and the development of complications of DM2
and the contradictory results in the literature regarding the
effect of LA and vitamin E on this disease, the present study
evaluated the effects of supplementation with these two
antioxidants on the lipid profile and insulin sensitivity of
patients with DM2.2. Materials and methods
A randomized, double-blind, placebo-controlled clinical trial
was conducted on 102 adult patients with DM2, ranging in age
from 38 to 75 years, who were registered at the Integrated
Health Nucleus (NIS) and Polyclinics of two neighborhoods in
Jundiaı´ city, Brazil. Patients with at least 2 years since the
diagnosis of the disease, without episodes of ketoacidosis and
with glycated hemoglobin (A1c) less than 7% [17] (result of the
last exam performed up to 4 months prior to selection) were
included in the study. Exclusion criteria were insulin therapy
at baseline or during the study, use of vitamin supplements
containing LA and/or vitamin E, pregnancy before or during
the study, smoking (>10 cigarettes/day), daily alcohol con-
sumption, presence of renal failure and cardiovascular
diseases, decompensation of DM2 due to infection, change
or introduction of new medication to the treatment of DM2,
and a family history of autoimmune disease. Each eligible
subject received one of the following treatments: capsules
containing 600 mg LA (LA group), capsules containing 800 mg
vitamin E (vitE group), capsules containing 600 mg LA + 800 mg
vitamin E (vitE + LA group), and placebo. The supplements
were taken daily for a period of 16 weeks and the participants
were advised to take the supplement always at the same time
of the day and to consume their habitual diet.
The size of the sample was determined as described by
Browner et al. [18] based on the ratio between the estimated
magnitude of the effect of the outcome variable (E) and its
standard deviation (S), which is 3.14 for the homeostasis
model assessment (HOMA) index. On the basis of these
parameters, 102 subjects were included in four groups.
Considering a possible loss to follow-up, a safety margin of
30% was determined, with a = 0.05 and b = 10%.
The recruitment of the study population and the flow chart
of the study are illustrated in Fig. 1.
2.1. Laboratory measurements
For the determination of the biochemical parameters, blood
sampleswere collected after a 12-h fast early in themorning by
peripheral venous puncture. Insulin was analyzed by an
immunofluorometric method using the AutoDELFIA Insulin
kit (BO80-101, PerkinElmer, USA). The reference value adopted
for fasting insulin was 25.0 mIU/mL [19]. To determine insulin
resistance, theHOMAindexwasusedaccording to the following
formula: HOMA = fasting glucose (mmol/L)  fasting insulin
(mIU/mL)/22.5 [17]usinga cut-off valueof 2.71% [20]. Serumtotal
cholesterol, HDL-c, TG and glucose levels were measured by
validated routine immunoenzymatic andcolorimetricmethods
in an automated analyzer (917 Automatic Analyzer, Roche/
Hitachi). LDL-c was estimated using the Friedewald equation.
The glucose reference values adopted were: <100 mg/dL
(normal), 100–126 mg/dL (glucose intolerance), and >126 mg/
dL (diabetes) [20]. All tests were performed in duplicate.
Plasma a-tocopherol concentrations were measured in
200 mL samples previously stored at 30 8C. After thawing,
200 mL ethanolwas added and themixturewas vortexed. Next,
5 mL hexane was added and the samples were mixed and
centrifuged at 700  g for 5 min. A 250 mL aliquot of each
[()TD$FIG]
Fig. 1 – Flow chart illustrating the recruitment of the patients for the study.
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resuspended in 200 mL of the mobile phase (70% acetonitrile,
20% methanol, and 10% dichloromethane). Next, 20 mL of the
mixture was injected into a high-performance liquid chro-
matograph (HPLC) (Shimadzu, System Controller SCL-10AVP)
equipped with a Rheodyne manual sample injector. The
chromatograms were integrated using the Class VP software
and calibration curves were constructed for the calculation of
a-tocopherol concentrations. Separation was performed on a
5-mm HyperClone ODS C18 analytical column (Phenomenex).
After collection of blood samples and application of a
questionnaire, the subjects were submitted to anthropometric
assessment (weight, height, and waist circumference mea-
surements).
The clinical protocol of this study (COEP No. 128/04) was in
accordance with the ethical guidelines of the National Health
Council (NHC). The clinical trial was registered at the ISRCTN
under the number 81379520. All subjects gave informed
consent to participate in the study.
2.2. Statistical analysis
The STATA program, version 10, was used for all statistical
analysis. Absolute and relative frequency, mean, standard
deviation, and confidence interval were used for description of
the sample. All variables were tested for normality. The
continuous variables of interest were analyzed by ANOVA,using Bonferroni correction, or by the Chi-square test. If a
variable did not meet the premises of ANOVA, logarithmic or
square root transformation was applied. Student’s t-test was
used for analysis of means of two independent variables.
Differences between proportions of categorical variables were
compared by the Chi-square test. The level of significance
accepted in this study was 5%.
3. Results
A total of 250 patients were initially contacted to participate in
the study, but 74 of them did not accept. By the exclusion
criteria 32 patients were not included in the study: 21 patients
required insulin therapy, and 11 had died at the time of
contact. Ten patients were excluded after the beginning of the
study: 8 who abandoned the study and 2 as a consequence of
insulin therapy. Therefore, the final sample consisted of 102
patients with DM2. Of these, 64.7% were females and 63.7%
were older than 60 years. Various signs and symptoms were
reported during the intervention, most of them due to the
disease itself (polyuria, 90.2%; nycturia, 79.4%; weakness,
71.6%, and sleepiness, 69.6%). The baseline characteristics of
the four groups are shown in Table 1.
The evaluation of plasma a-tocopherol concentrations
before and after supplementation with 800 mg/day confirmed
the efficacy of the intervention in recovering from vitamin E
Table 1 – Characteristics of the study population at baseline.







n % n % n % n % n %
Gender
Male 16 61.5 18 72.0 17 68.0 15 57.7 66 64.7 0.72a
Female 10 38.5 7 28.0 8 32.0 11 42.3 36 35.3
Age (years)
39–49 3 11.5 2 8.0 3 12.0 2 7.7 10 9.8 0.44b
50–59 9 34.7 4 16.0 8 32.0 6 23.1 27 26.5
60–69 11 42.3 13 52.0 11 44.0 13 50.0 48 47.1
70 3 11.5 6 24.0 3 12.0 5 19.2 17 16.6
BMI (kg/m2)
<25 4 15.4 2 8.0 1 4.0 3 11.5 10 9.8 0.75a
25–30 14 53.8 14 56.0 17 68.0 15 57.7 60 58.8
>30 8 30.8 9 36.0 7 28.0 8 30.8 32 31.4
Marital status
Single 4 15.4 2 8.0 3 12.0 3 11.5 12 11.8 0.11a
Married 20 77.0 14 56.0 18 72.0 15 57.7 67 65.6
Divorced 1 3.8 4 16.0 2 8.0 4 15.4 11 10.8
Widowed 1 3.8 5 20.0 2 8.0 4 15.4 12 11.8
Occupation
Do not work 9 34.6 10 40.0 6 24.0 7 26.9 32 31.4 0.61a
Work 7 26.9 4 16.0 5 20.0 7 26.9 23 22.5
Retired 10 38.5 11 44.0 14 56.0 12 46.2 47 46.1
Education (years)
None 3 11.5 3 12.0 3 12.0 3 11.5 12 11.8 0.90a
<8 18 69.3 17 68.0 18 72.0 20 77.0 73 71.5
8–12 1 3.8 3 12.0 1 4.0 1 3.8 6 5.9
>12 4 15.4 2 8.0 3 12.0 2 7.7 11 10.8
Per capita income (MBW)
<0.59 7 26.9 13 52.0 9 36.0 13 50.0 42 41.2 0.99a
0.60–0.99 4 15.4 4 16.0 3 12.0 4 15.4 15 14.7
1.00–1.40 9 34.6 4 16.0 8 32.0 3 11.5 24 23.5
1.50–3.00 6 23.1 4 16.0 5 20.0 6 23.1 21 20.6
Smoking status
Yes 3 11.5 3 12.0 3 12.0 2 7.7 11 89.2 0.95a
No 23 88.5 22 88.0 22 88.0 24 92.3 91 10.8
Alcohol consumption
Yes 8 30.8 4 16.0 6 24.0 8 30.8 26 25.5 0.56a
No 18 69.2 21 84.0 19 76.0 18 69.2 76 74.5
vitE, vitamin E; LA, lipoic acid; BMI, body mass index; MBW, minimum brazilian wage (equivalent to 239.61 US$ dollars).
a Chi-square.
b ANOVA with Bonferroni.
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tocopherol deficiency and an increase in the number of those
with acceptable levelswere observed in the vitamin E group. In
the vitamin E + LA group, the number of patients with vitamin
deficiency and with low a-tocopherol levels was reduced and
the number of those with acceptable levels was increased.
Based on the Student t-test, vitamin Emean differences before
and after supplementation in the vitE and vitE + LA groups
were statistically significant (p < 0.001) (Table 2).
Descriptive analysis of the lipid profile (total cholesterol,
HDL-c, LDL-c, and TG), glucose and insulin concentrations,
and the HOMA index are shown in Table 3. The results are
reported as mean, standard deviation, and 95% confidence
interval betweenmeans. No significant differences in the lipid
profile, glucose or insulin concentrations were observed
before and after supplementation. In relation to the HOMA
index, themean values of fasting glycemia observed in the LA,
vitE, vitE + LA, and placebo groups before supplementationwere compatible with the classification of diabetes [17]. The
mean indices observed in the supplemented groups before
and after supplementation indicated glucose intolerance.
ANOVA demonstrated that the use of antioxidants for 16
weeks did not exert a significant effect in those patients.
4. Discussion
In the present study, supplementation with LA and vitamin E
alone or in combination had no effect on the lipid profile or
insulin sensitivity of patients with DM2, with no changes in
the concentrations of total cholesterol, cholesterol fractions,
TG, and HOMA index.
The plasma concentrations of LA were not determined
because of the difficulty in the measurement of this antioxi-
dant [21]. However, observation of the results of plasma
vitamin E concentrations showed that the patients of the vitE
Table 2 – Percentage of patients with deficient, low and acceptable vitamin E/total cholesterol ratio before and after





















<2.2 3 6 5 2 7 2 3 6
Deficient (11.5) (23.1) (20.0) (8.0) (28.0) (8.0) (11.5) (23.1)
2.2–5.1 16 12 16 8 12 6 15 12
Low (61.5) (46.2) (64.0) (32.0) (48.0) (24.0) (57.7) (46.2)
>5.2 7 8 4 15 6 17 8 8
Acceptable (26.9) (30.8) (16.0) (60.0) (24.0) (68.0) (30.8) (30.8)
vitE (mmol/L) 4.90 4.54 4.33 7.95 3.84 10.10 5.16 4.54
(SD) (2.96) (3.06) (3.70) (5.77) (2.00) (8.99) (3.36) (2.97)
p-Value* 0.67 0.001 <0.001 0.48
vitE, vitamin E; LA, lipoic acid; SD, standard deviation.
* Student’s t-test.
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view of the double-blind design of the study, all subjects were
followed up without distinction, a fact suggesting that the
participants in the LA group presented the same behavior.
Some of the explanations regarding the lack of effect of
supplementation with 400 IU vitamin E/day reported in the
HeartOutcomesPreventionEvaluation (HOPE)study [22]maybe
used to interpret the results of the present trial. One of the
causes refers to the age of the subjects selected, which ranged
frommiddle to old age. As a consequence, the complications of
diabetes are already acting for a long period of time in these
individuals, impairing the effects of vitamin E which is more
effective in patients with recent alterations. Another explana-
tion is related to the concentrationofvitaminEused indifferent
studies. Some investigators favor the administration of mega-
doses of a-tocopherol (>1200mg/day) [23]. Lower doses of 400
and 800 IU/daywere used in the HOPE study and in the present
investigation, respectively. According to Opara [24], supple-
mental doses of a single antioxidant such as vitamin Emight be
beneficial in diabetes. On the other hand, antioxidants interact
in the biochemical defense systemagainst reactive species and
the use of elevated doses of a single antioxidant may result in
disturbances of the antioxidant/pro-oxidant balance.
Marangon et al. [25] studied the effect of supplementation
with LA (600 mg/day), a-tocopherol (400 IU/day), and LA
(600 mg/day) + a-tocopherol (400 IU/day) for 4 months in 31
healthy subjects. The authors observed a reduction inmarkers
of oxidative stress in the group receiving the combination of
the two antioxidants when compared to the administration of
either antioxidant alone. No significant differences in anthro-
pometric measures or lipid profile were observed.
Most clinical trials on the effects of antioxidant treatment
are limited in terms of duration and sample size. Studies using
LA suggest that the antioxidant activity of this acid might be
related to its additional role in glucose transport in muscle
cells [5].
With respect to vitamin E, elevated, unchanged or reduced
levels have been observed in DM2 and the discrepancies
between studies in terms of the preventive or deleterious
effects of this vitamin on the lipid profile might be related tothe doses administered [26].In the present study, 74.5% of the
patients with DM2 presented deficient and low concentrations
of a-tocopherol. Although evidence indicates that LA acts by
recycling vitamin E, thus increasing its levels, no significant
difference in plasma a-tocopherol levels was observed in the
group supplemented with this acid when compared to the
vitamin E group.
According to Devaraj and Jialal [27], low concentrations of
vitamin E are associated with an increased incidence of
diabetes. Some studies suggest that the lower concentrations
of antioxidants observed in patients with DM2 are due to the
higher requirement of these antioxidants in the fight against
oxidative stress caused by hyperglycemia [28,29]. However,
the assessment of the requirements of antioxidants in DM2 is
difficult. Rizzo et al. [30] found out that supplementation with
nutritional doses of vitamin E + vitamin C for a prolonged
period of time had no effects on fasting glycemia. However, a
previous study clearly demonstrated that pharmacological
doses of vitamin E are associated with an increased action of
insulin and improved lipid profile in this population [31].
All subjects of this study presented mean total cholesterol,
HDL-c and LDL-c levels within normal ranges. With respect to
TG, only the LA group had acceptable levels at baseline
according to the NCEP-ATP III criteria, with no significant
differences after supplementation.
According to the CopenhagenMale Study [32] a high fasting
TG concentration is a strong predictor of mortality due to
coronary artery disease, regardless of the presence of other
risk factors. Brunzell and Ayyobi [33] also observed the
presence of elevated TG concentrations in patients with
DM2, with LDL-c levels close to the reference range, but with
low HDL-c concentrations. Thus, the lipid profile of the
patients included in our study was compatible with an
increased risk for cardiovascular diseases.
Kuusisto et al. [34], followingupolder adultmaleswithDM2
for 7 years, showed that hypertriglyceridemia and reduced
HDL-c predispose to the occurrence of cardiovascular events.
Recently, a randomized trial demonstrated an association
between serum lipoproteins and insulin resistance (assessed
by the HOMA index) in patients with DM2 suggesting that the
Table 3 – Lipid profile, glucose and insulin concentrations, and the HOMA index of the study population before and after
supplementation with lipoic acid (LA), vitamin E (vitE), vitamin E + lipoic acid (vitE + LA), and placebo (n = 102).
Variables Before supplementation After supplementation p-Value*
Mean (SD) 95% CI Mean (SD) 95% CI
TC (mg/dL)
LA 184.2 (62.0) 160.4–208.0 176.3 (40.3) 160.8–191.8 0.75
vitE 196.1 (53.1) 175.3–216.9 189.1 (34.2) 175.7–202.5
vitE + LA 199.2 (48.4) 180.3–218.1 191.2 (47.9) 172.5–209.9
Placebo 194.0 (53.9) 173.3–214.7 200.5 (58.5) 178.1–222.9
HDL-c (mg/dL)
LA 52.2 (22.3) 43.7–60.7 48.8 (14.6) 43.2–54.4 0.79
vitE 49.0 (20.2) 41.1–56.9 48.4 (13.3) 43.2–53.6
vitE + LA 44.0 (16.3) 37.7–50.3 45.2 (14.2) 39.7–50.7
Placebo 46.8 (12.1) 42.2–51.0 48.1 (14.6) 42.5–53.7
LDL-c (mg/dL)
LA 102.9 (38.5) 88.2–117.6 100.7 (36.1) 86.9–114.5 0.50
vitE 117.7 (40.8) 101.8–133.6 109.6 (30.6) 97.7–121.5
vitE + LA 129.9 (58.3) 107.1–152.7 113.0 (43.2) 96.1–129.9
Placebo 115.1 (54.7) 94.1–136.1 117.1 (59.0) 94.5–139.7
TG (mg/dL)
LA 149.9 (81.6) 118.6–181.2 133.4 (78.6) 103.2–163.6 0.79
vitE 159.7 (78.7) 128.9–190.5 155.5 (69.8) 128.2–182.8
vitE + LA 222.8 (426.5) 55.6–390.0 164.5 (92.1) 128.4–200.6
Placebo 200.8 (228.5) 112.1–288.7 184.5 (172.1) 118.4–250.6
Glucose (mg/dL)
LA 134.0 (87.8) 100.3–167.7 120.8 (46.0) 103.1–138.5 0.70
vitE 125.2 (57.3) 103.5–147.2 124.2 (52.1) 104.2–144.2
vitE + LA 135.6 (63.6) 111.2–160.0 117.9 (32.0) 105.6–130.2
Placebo 134.6 (70.3) 107.4–161.8 134.3 (75.8) 105.2–163.4
Insulin (mIU/mL)
LA 13.1 (5.9) 10.8–15.4 12.2 (10.4) 8.3–16.1 0.54
vitE 11.9 (9.4) 8.3–15.5 12.7 (8.3) 9.5–15.9
vitE + LA 9.8 (4.8) 8.0–11.6 11.9 (7.6) 9.0–14.8
Placebo 12.7 (7.8) 9.8–15.6 12.7 (7.5) 9.9–15.5
HOMA index**
LA 4.8 (5.6) 2.7–6.9 4.2 (5.5) 2.1–6.3 0.77
vitE 3.5 (3.3) 2.2–4.8 3.9 (2.8) 2.9–4.9
vitE + LA 3.2 (1.8) 2.5–3.9 3.3 (2.1) 2.5–4.1
Placebo 4.3 (3.8) 2.8–5.8 4.1 (3.5) 2.8–5.4
SD, standard deviation; TC, total cholesterol; HDL-c, high density lipoprotein cholesterol; LDL-c, low density lipoprotein cholesterol; TG,
triglycerides; vitE, vitamin E; LA, lipoic acid; HOMA, homeostasis model assessment.
* ANOVA with Bonferroni correction.
** Logarithmic transformation.
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patients at increased risk for cardiovascular disease [35].
Insulin plays a fundamental role in the metabolism of TG,
normally reducing the availability of large TG-rich particles
that are synthesized by a distinct pathway when compared to
smaller VLDL (very low-density lipoprotein) particles. As a
consequence, insulin resistance would be involved in the
etiology of various illnesses such as DM2, coronary disease,
and arterial hypertension [36].
In the present study, there were 54.3% and 49.7% DM2
patients with a HOMA index > 2.7 at baseline and at the end of
the intervention, respectively. There were no significant
differences between andwithin groups after supplementation
(p = 0.77). Mean HOMA index values were similar to those
reported in other studies [37,38].
In a placebo-controlled clinical trial, Jacob et al. [23]
demonstrated that oral administration of LA modulates
insulin sensitivity, with this acid stimulating the uptake of
glucose and thus exerting an insulin-sensitizing action.Apparently, the role of LA and vitamin E in DM2 is
controversial considering the positive, negative and neutral
effects of these antioxidants in the disease. Despite the
promising therapeutic applicability of LA, this substance is
labile and the lack of chemical stability impairs the production
of an adequate pharmaceutical form for oral or topical
administration [39], which may have influenced our results.
Although this study found no beneficial effect of treatment
with these two antioxidants in terms of reduction of insulin
resistance or improvement of lipid profile, supplementation
with LA and vitamin E for the prevention or treatment of
complications of DM2 should be better investigated in large
longitudinal epidemiological studies.
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